### Edgar Filing: Prothena Corp plc - Form 4

Prothena Cor	p plc									
Form 4	F									
May 26, 201:								OMB A	PPROVAL	
FORM	<b>4</b> UNITED S	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							3235-0287	
Check thi									January 31,	
if no long subject to Section 1	6. SIAIEM	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP ( SECURITIES						Expires: 2005 Estimated average burden hours per		
Form 4 or Form 5				( . ) . <b>f</b> 41.	G			response	0.5	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type R	Responses)									
1. Name and Address of Reporting Person <u>*</u> COLLIER RICHARD T			2. Issuer Name <b>and</b> Ticker or Trading Symbol Prothena Corp plc [PRTA]				5. Relationship of Reporting Person(s) to Issuer			
(Last) (First) (Middle)			3. Date of Earliest Transaction				(Check all applicable)			
(Last) (Filst) (Middle)			(Month/Day/Year)				_X_ Director 10% Owner			
C/O PROTHENA BIOSCIENCES INC, 650 GATEWAY BOULEVARD			05/22/2015				Officer (give title below)     Other (specify below)			
				. If Amendment, Date Original iled(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
SOUTH SA FRANCISC	N O, CA 94080						Person	More than One R	eporting	
(City)	(State) (	(Zip)	Table	e I - Non-D	erivative S	ecurities Ac	quired, Disposed o	f, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Executio any		3. Transactio Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Ordinary Shares, par value \$0.01 per share				Code V	Amount	(D) Price	(Instr. 3 and 4) 1,219	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Edgar Filing: Prothena Corp plc - Form 4

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities8(Instr. 3 and 4)9(Instr. 3 and 4)9	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 34.04	05/22/2015		А	15,000	<u>(1)</u>	05/22/2025	Ordinary Shares	15,000

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
COLLIER RICHARD T C/O PROTHENA BIOSCIENCES INC 650 GATEWAY BOULEVARD SOUTH SAN FRANCISCO, CA 94080	Х					
Signatures						
/s/ A.W. Homan, as Attorney in Fact for Collier	Γ.	05/26/2015				
**Signature of Reporting Person			Da	ite		
Explanation of Respon	200'					

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the(1) earlier of the first anniversary of the grant date or the day prior to the annual general meeting in 2016 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.